Patent · US Active

Antibodies against ERBB3 and uses thereof

US8961966B2 · kind B2 · utility

12Cited by

9References

15Claims

0Family size

Assignee

Merrimack Pharmaceuticals, Inc. · US

Inventors

Birgit Schoeberl · Cambridge, US
Ulrik Nielsen · Quincy, US
Michael Feldhaus · Lebanon, US
Arumugam Muruganandam · Bengaluru, IN
David Buckler · Mount Olive, US

Key dates

Filing date	Oct 14, 2010
Grant date	Feb 24, 2015
Priority date	—
Expiry date	Dec 12, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.